非小细胞肺癌靶向治疗药物的临床研究进展  

Clinical research progress on target therapies for non-small cell lung cancer

作　　者：刘禹杉 何馨彤 杜荣蓉 张紫筝 曲连悦[1] 林建阳[1] LIU Yushan;HE Xintong;DU Rongrong;ZHANG Zizheng;QU Lianyue;LIN Jianyang(Department of Pharmacy,The First Hospital of China Medical University,Shenyang 110001,China;College of Pharmaceutical Science,China Medical University,Shenyang 110122,China)

机构地区：[1]中国医科大学附属第一医院药学部,辽宁沈阳110001 [2]中国医科大学药学院,辽宁沈阳110122

出　　处：《药物评价研究》2021年第2期432-439,共8页Drug Evaluation Research

基　　金：国家自然科学基金青年科学基金资助项目(81302841);辽宁省高等学校优秀人才支持计划资助项目(LJQ2014086)。

摘　　要：非小细胞肺癌(NSCLC)是恶化程度高、治疗难度大的肺部癌症,其发生常与多种相关基因靶点突变或通路异常有关,如表皮生长因子受体突变、间变性淋巴瘤激酶重排等。靶向药物的出现为NSCLC治疗提供了新方向,吉非替尼、厄洛替尼、奥希替尼、劳拉替尼及多靶点抑制剂为常见的靶向治疗药,临床试验结果也显示出一定的疗效。对近年来国内外有关NSCLC相关靶向治疗药物中的部分值得引起注意的临床试验研究结果进行综述,以期为制定相关的临床用药方案提供依据。Non-small cell lung cancer(NSCLC) is a kind of high-deterioration as well as difficult-to-treat cancer, which is commonly associated with a variety kinds of targets’ mutations and abnormal pathways, such as epidermal growth factor receptor,anaplasticlymphoma kinase, et al. The emergence of target therapies provides novel orientations for the treatments of NSCLC patients. Recently, several clinical trials show, to some extent, extraordinary efficacy, like gefitinib, erlotinib, osimertinib, lorlatinib,some multi-target inhibitors and so on. This article reviews some results of several trials at home and abroad which could give more evidence, so as to support doctors in designing a more effective clinical therapy for the patients.

关 键 词：非小细胞肺癌 表皮生长因子受体 间变性淋巴瘤激酶 多靶点抑制剂 靶向药物 临床研究 

分 类 号：R944.5[医药卫生—药剂学]